Deep Dive: R&D 2024

Just a few short months into the new year and already the crackle of innovation has begun to permeate across the pharma R&D landscape. Expectations for 2024 were already high, particularly in the gene editing space, after news broke that the first CRISPR-based therapy had received official regulatory approval, first in the UK and now in the US.

A decade in the making, CRISPR is a shining example of how scientific curiosity and collaboration can produce life-changing treatment options for patients around the world. And so, to celebrate this milestone achievement, it seems only fitting to kick off 2024 – the year of CRISPR-based therapeutics – with a look back at key points in the technology’s development journey.

On the subject of patients urgently awaiting new therapeutic options, millions of people living with rare diseases desperately need innovation in diagnosis, treatment, and care, but how can we get new solutions to them faster? In this month’s Deep Dive, join Alexion’s Soraya Bekkali as she considers the possibilities.

Elsewhere in this issue, pharmaphorum editor-in-chief Jonah Comstock hits the floor at the 42nd annual JP Morgan Health conference to find out how attitudes towards AI in R&D are changing, blood donation centres infuse new life into the cell and gene therapy space, and we find out what it takes to navigate the complex and evolving landscape of clinical trial supply management.

For all this and more, read on.

Eloise McLennan – editor, Deep Dive